Literature DB >> 1715698

Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: control of IGF signalling to bone cells by IGFBP-3-specific proteolysis?

C Schmid1, J Rutishauser, I Schläpfer, E R Froesch, J Zapf.   

Abstract

IGFBP-3 is the predominant IGFBP in serum and the major IGFBP secreted by osteoblasts. Native and recombinant IGFBP-3 and a truncated form lacking the carboxyterminal third were tested for their effects on 2 osteoblastic cell lines. Intact but not truncated IGFBP-3 blocked IGF I-stimulated DNA and glycogen synthesis. Inhibition was dose-dependent and found whenever the concentration of intact IGFBP-3 exceeded the concentration of IGF I. Truncated IGFBP-3 appears to result from proteolytic cleavage and does occur in vivo. The loss of inhibition by IGFBP-3 may be regulated at the site of IGF target cells and thus be essential for IGF I-induced osteoblast growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715698     DOI: 10.1016/0006-291x(91)91410-e

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  The insulin-like growth factor family of ligands, receptors, and binding proteins.

Authors:  R F Krywicki; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

Review 3.  The role of the insulin‑like growth factor (IGF) axis in osteogenic and odontogenic differentiation.

Authors:  H Al-Kharobi; R El-Gendy; D A Devine; J Beattie
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

4.  Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults.

Authors:  S Khosla; A A Hassoun; B K Baker; F Liu; N N Zein; M P Whyte; C A Reasner; T B Nippoldt; R D Tiegs; R L Hintz; C A Conover
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

5.  Postsynthetic regulation of insulin-like growth factor-binding protein-3 by MCF-7 human breast cancer cells in culture.

Authors:  R W Grimes; A Manni; J M Hammond
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma.

Authors:  Y Gong; L Cui; G Y Minuk
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

7.  Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.

Authors:  Y Imai; W H Busby; C E Smith; J B Clarke; A J Garmong; G D Horwitz; C Rees; D R Clemmons
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

8.  Interaction of insulin-like growth factor binding protein-3 with latent transforming growth factor-beta binding protein-1.

Authors:  Yaoting Gui; Liam J Murphy
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

9.  Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats.

Authors:  J Zapf; C Hauri; E Futo; M Hussain; J Rutishauser; C A Maack; E R Froesch
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I.

Authors:  J I Jones; A Gockerman; W H Busby; C Camacho-Hubner; D R Clemmons
Journal:  J Cell Biol       Date:  1993-05       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.